# Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

> **NCT04308330** · PHASE1 · RECRUITING · sponsor: **New York Medical College** · enrollment: 30 (estimated)

## Conditions studied

- Ewing Sarcoma
- Rhabdomyosarcoma
- Wilms Tumor
- Neuroblastoma
- Hepatoblastoma
- Germ Cell Tumor

## Interventions

- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT04308330
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-17
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04308330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04308330, "Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04308330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*